Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the MDM2 ‐ MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancer

28 Feb 2025

Abstract excerpt

Targeting the heterodimer MDM2/MDM4 is a novel and effective route for the reactivation of wild-type p53 in human tumors with reduced toxicity in nontransformed cells. To improve the therapeutic potential of peptides that interfere with MDM4 binding to MDM2, we demonstrated the tumor-suppressive activity of a short peptide (Pep3S), which is composed of the last five amino acids of the MDM4 protein. Compared to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer-related Molecular Pathways
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40022459
DOI: 10.1002/1878-0261.70006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the MDM2 ‐ MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancerPMID 40022459Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer CellsSemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?Semantic proximity Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

The MDM2-p53 pathway revisitedSemantic proximity Read ↗

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell DeathSemantic proximity Read ↗

Translating p53-based therapies for cancer into the clinic.Semantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets SeriousSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.